USD 2.16
(-8.86%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 71.25 Million USD | 16.08% |
2022 | 57.11 Million USD | 53.33% |
2021 | 37.25 Million USD | 6.52% |
2020 | 34.97 Million USD | -18.72% |
2019 | 43.02 Million USD | -11.81% |
2018 | 48.78 Million USD | 14.57% |
2017 | 42.57 Million USD | 30.57% |
2016 | 32.61 Million USD | 30.73% |
2015 | 24.94 Million USD | 22.47% |
2014 | 20.36 Million USD | 14.22% |
2013 | 17.83 Million USD | 15.02% |
2012 | 15.5 Million USD | 25.68% |
2011 | 12.33 Million USD | -11.93% |
2010 | 14 Million USD | -42.83% |
2009 | 24.49 Million USD | 24.76% |
2008 | 19.63 Million USD | 1.99% |
2007 | 19.25 Million USD | 35.81% |
2006 | 14.17 Million USD | 62.5% |
2005 | 8.72 Million USD | 13.29% |
2004 | 7.7 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 17.55 Million USD | -2.73% |
2024 Q2 | 19.37 Million USD | 17.96% |
2023 Q1 | 17.43 Million USD | 7.8% |
2023 Q4 | 18.04 Million USD | 5.43% |
2023 FY | 66.3 Million USD | 16.08% |
2023 Q2 | 17.73 Million USD | 1.73% |
2023 Q3 | 17.11 Million USD | -3.49% |
2022 Q2 | 12.1 Million USD | 13.14% |
2022 FY | 57.11 Million USD | 53.33% |
2022 Q3 | 18.15 Million USD | 50.02% |
2022 Q4 | 16.17 Million USD | -10.92% |
2022 Q1 | 10.69 Million USD | 8.23% |
2021 Q3 | 9.71 Million USD | 6.74% |
2021 Q4 | 9.88 Million USD | 1.74% |
2021 FY | 37.25 Million USD | 6.52% |
2021 Q1 | 8.55 Million USD | -2.55% |
2021 Q2 | 9.1 Million USD | 6.33% |
2020 Q2 | 8.83 Million USD | 0.0% |
2020 FY | 34.97 Million USD | -18.72% |
2020 Q1 | 8.83 Million USD | -28.07% |
2020 Q4 | 8.78 Million USD | -1.38% |
2020 Q3 | 8.9 Million USD | 0.76% |
2019 Q4 | 12.28 Million USD | 0.0% |
2019 FY | 43.02 Million USD | -11.81% |
2019 Q1 | 9.41 Million USD | -20.55% |
2019 Q2 | 9.41 Million USD | 0.0% |
2019 Q3 | 12.28 Million USD | 30.5% |
2018 Q4 | 11.84 Million USD | 0.0% |
2018 FY | 48.78 Million USD | 14.57% |
2018 Q1 | 12.73 Million USD | 6.17% |
2018 Q2 | 12.73 Million USD | 0.0% |
2018 Q3 | 11.84 Million USD | -6.99% |
2017 Q3 | 11.99 Million USD | 28.26% |
2017 Q2 | 9.35 Million USD | 0.0% |
2017 Q4 | 11.99 Million USD | 0.0% |
2017 Q1 | 9.35 Million USD | 9.57% |
2017 FY | 42.57 Million USD | 30.57% |
2016 Q4 | 8.53 Million USD | 0.0% |
2016 Q1 | 7.99 Million USD | 9.31% |
2016 Q3 | 8.53 Million USD | 6.82% |
2016 Q2 | 7.99 Million USD | 0.0% |
2016 FY | 32.61 Million USD | 30.73% |
2015 Q1 | 5.24 Million USD | 4.66% |
2015 Q3 | 7.31 Million USD | 39.28% |
2015 Q4 | 7.31 Million USD | 0.0% |
2015 FY | 24.94 Million USD | 22.47% |
2015 Q2 | 5.24 Million USD | 0.0% |
2014 Q2 | 5.21 Million USD | 0.0% |
2014 FY | 20.36 Million USD | 14.22% |
2014 Q4 | 5.01 Million USD | 0.0% |
2014 Q3 | 5.01 Million USD | -3.84% |
2014 Q1 | 5.21 Million USD | 31.9% |
2013 Q2 | 5.01 Million USD | 0.0% |
2013 FY | 17.83 Million USD | 15.02% |
2013 Q1 | 5.01 Million USD | 21.76% |
2013 Q3 | 3.95 Million USD | -21.07% |
2013 Q4 | 3.95 Million USD | 0.0% |
2012 Q2 | -3.8 Million USD | 0.0% |
2012 Q1 | -3.8 Million USD | -23.52% |
2012 Q3 | 4.22 Million USD | 210.79% |
2012 Q4 | 4.11 Million USD | -2.49% |
2012 FY | 15.5 Million USD | 25.68% |
2011 Q1 | -3.08 Million USD | 11.93% |
2011 Q4 | -3.08 Million USD | 0.0% |
2011 FY | 12.33 Million USD | -11.93% |
2011 Q2 | -3.08 Million USD | 0.0% |
2011 Q3 | -3.08 Million USD | 0.0% |
2010 Q4 | -3.5 Million USD | 0.0% |
2010 Q2 | -3.5 Million USD | 0.0% |
2010 Q3 | -3.5 Million USD | 0.0% |
2010 Q1 | -3.5 Million USD | 42.83% |
2010 FY | 14 Million USD | -42.83% |
2009 Q1 | -6.12 Million USD | -24.76% |
2009 Q3 | -6.12 Million USD | 0.0% |
2009 FY | 24.49 Million USD | 24.76% |
2009 Q4 | -6.12 Million USD | 0.0% |
2009 Q2 | -6.12 Million USD | 0.0% |
2008 Q2 | -4.9 Million USD | 0.0% |
2008 Q4 | -4.9 Million USD | 0.0% |
2008 Q1 | -4.9 Million USD | -202.75% |
2008 Q3 | -4.9 Million USD | 0.0% |
2008 FY | 19.63 Million USD | 1.99% |
2007 Q3 | 4.77 Million USD | 0.0% |
2007 FY | 19.25 Million USD | 35.81% |
2007 Q4 | 4.77 Million USD | 0.0% |
2007 Q1 | 4.77 Million USD | 39.78% |
2007 Q2 | 4.77 Million USD | 0.0% |
2006 Q3 | 3.41 Million USD | 0.0% |
2006 Q2 | 3.41 Million USD | 0.0% |
2006 Q1 | 3.41 Million USD | 59.41% |
2006 FY | 14.17 Million USD | 62.5% |
2006 Q4 | 3.41 Million USD | 0.0% |
2005 FY | 8.72 Million USD | 13.29% |
2005 Q2 | 2.14 Million USD | 0.0% |
2005 Q3 | 2.14 Million USD | 0.0% |
2005 Q1 | 2.14 Million USD | 13.43% |
2005 Q4 | 2.14 Million USD | 0.0% |
2004 Q4 | 1.89 Million USD | 0.0% |
2004 Q2 | 1.89 Million USD | 0.0% |
2004 Q3 | 1.89 Million USD | 0.0% |
2004 Q1 | 1.89 Million USD | 0.0% |
2004 FY | 7.7 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bionano Genomics, Inc. | 148.99 Million USD | 52.175% |
Prenetics Global Limited | 60.73 Million USD | -17.32% |
Star Equity Holdings, Inc. | 16.27 Million USD | -337.906% |
CareDx, Inc | 277.76 Million USD | 74.347% |
Exact Sciences Corporation | 2.06 Billion USD | 96.542% |
Exagen Inc. | 52.29 Million USD | -36.263% |
Inotiv, Inc. | 246.9 Million USD | 71.14% |
Guardant Health, Inc. | 901.62 Million USD | 92.097% |
Biodesix, Inc. | 77.41 Million USD | 7.961% |
BioNexus Gene Lab Corp. | 3.92 Million USD | -1716.325% |
Precipio, Inc. | 13.63 Million USD | -422.481% |
iSpecimen Inc. | 16.27 Million USD | -337.764% |
Natera, Inc. | 938.98 Million USD | 92.411% |
Aspira Women's Health Inc. | 24.11 Million USD | -195.496% |
Standard BioTools Inc. | 113.48 Million USD | 37.213% |
23andMe Holding Co. | 420.73 Million USD | 83.064% |
Castle Biosciences, Inc. | 242.78 Million USD | 70.65% |
Personalis, Inc. | 128.14 Million USD | 44.394% |
Aclaris Therapeutics, Inc. | 110.52 Million USD | 35.53% |
Applied DNA Sciences, Inc. | 16.48 Million USD | -332.202% |
OpGen, Inc. | 30.65 Million USD | -132.423% |
T2 Biosystems, Inc. | 41.49 Million USD | -71.726% |
Myriad Genetics, Inc. | 600.1 Million USD | 88.126% |
ICON Public Limited Company | 755.64 Million USD | 90.57% |
NeoGenomics, Inc. | 341.25 Million USD | 79.119% |
Star Equity Holdings, Inc. | 16.27 Million USD | -337.906% |
IDEXX Laboratories, Inc. | 1.09 Billion USD | 93.48% |
RadNet, Inc. | 268.87 Million USD | 73.499% |
Psychemedics Corporation | 11.33 Million USD | -528.692% |
Illumina, Inc. | 3.81 Billion USD | 98.131% |
Check-Cap Ltd. | 19.28 Million USD | -269.451% |
Twist Bioscience Corporation | 354.18 Million USD | 79.881% |
DarioHealth Corp. | 62.17 Million USD | -14.609% |
Fulgent Genetics, Inc. | 171.9 Million USD | 58.549% |
Sera Prognostics, Inc. | 39.91 Million USD | -78.51% |
ENDRA Life Sciences Inc. | 10.52 Million USD | -577.291% |
OPKO Health, Inc. | 574.68 Million USD | 87.601% |
Medpace Holdings, Inc. | 187.68 Million USD | 62.033% |
Neogen Corporation | 405.23 Million USD | 82.416% |
Intelligent Bio Solutions Inc. | 11.7 Million USD | -508.568% |
Prenetics Global Limited | 60.73 Million USD | -17.32% |
Mainz Biomed B.V. | 27.15 Million USD | -162.411% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -712.975% |
Trinity Biotech plc | 46.49 Million USD | -53.255% |
Neuronetics, Inc. | 82.25 Million USD | 13.376% |
Sotera Health Company | 300.46 Million USD | 76.285% |
bioAffinity Technologies, Inc. | 8.76 Million USD | -712.975% |